ConductScience.org, home

Paper27214717

Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A.

Carlsson M and 4 others. Haemophilia, 1997. Cited by 100 papers, by iCite.

Cite this record

ConductScience Library. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Papers, record 27214717. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27214717

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A.
PubMed
Journal
Haemophilia
PubMed
Year
1997
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
100
iCite
Relative citation ratio, by iCite
3.97
iCite
Revised in PubMed
2022-03-10
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Carlsson MM
2Berntorp EE
3Björkman SS
4Lethagen SS
5Ljung RR

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02622646Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A PatientsResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.

PMIDTitleJournalYearIn PapersSource
42257072Impact of Low Dose Prophylaxis (LDP) on spontaneous bleeds in Hemophilia-A: A Bicentre study from Pakistan.Pak J Med Sci2026https://conductscience.org/library/papers/42257072PubMed
36810557Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors.Hematol Rep2023https://conductscience.org/library/papers/36810557PubMed
35280975Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study).TH Open2022https://conductscience.org/library/papers/35280975PubMed
34531230Patient-centered approach to managing factor XIII deficiency.BMJ Case Rep2021https://conductscience.org/library/papers/34531230PubMed
34407214Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.Cochrane Database Syst Rev2021https://conductscience.org/library/papers/34407214PubMed
34349040Clinical Analysis of Hospitalized Patients with Hemophilia A: Single-hemophilia Treatment Center Experience in Korea over 10 years.Blood Res2021https://conductscience.org/library/papers/34349040PubMed
33733034Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products.Res Pract Thromb Haemost2021https://conductscience.org/library/papers/33733034PubMed
33506480A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.Thromb Haemost2021https://conductscience.org/library/papers/33506480PubMed
32851288PK-tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital.Pediatr Investig2019https://conductscience.org/library/papers/32851288PubMed
32326156Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?Pharmaceutics2020https://conductscience.org/library/papers/32326156PubMed
30633808Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.Br J Clin Pharmacol2019https://conductscience.org/library/papers/30633808PubMed
29039750Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.Pharmaceutics2017https://conductscience.org/library/papers/29039750PubMed
28335525The History of Clotting Factor Concentrates Pharmacokinetics.J Clin Med2017https://conductscience.org/library/papers/28335525PubMed
27833753Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A.BMC Hematol2016https://conductscience.org/library/papers/27833753PubMed
27721364Pediatric Dosing and Body Size in Biotherapeutics.Pharmaceutics2010https://conductscience.org/library/papers/27721364PubMed
27390359A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.Haematologica2016https://conductscience.org/library/papers/27390359PubMed
23908669Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.Korean J Pediatr2013https://conductscience.org/library/papers/23908669PubMed
23620343Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.J Pharm Sci2013https://conductscience.org/library/papers/23620343PubMed
20398185
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
J Thromb Haemost2010https://conductscience.org/library/papers/20398185PubMed
20234780Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Vasc Health Risk Manag2010https://conductscience.org/library/papers/20234780PubMed

See all 23 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/27214717

GET https://conductscience.org/api/papers/v1/27214717/cited_by?page=2